Armata Pharmaceuticals Submits Phase 3 Protocol for AP-SA02 to FDA
Armata Pharmaceuticals has submitted the Phase 3 protocol for AP-SA02, targeting Staphylococcus aureus infections. This submission follows FDA feedback and includes plans to initiate the study in late 2026, supported by $28.7 million in funding from the Department of Defense.
Theia Market Signal Identification - AI Assisted
Armata Pharmaceuticals Inc. has submitted its Phase 3 protocol for AP-SA02, targeting Staphylococcus aureus infections, to the FDA. The submission incorporates comments from an End-of-Phase 2 meeting and addresses various regulatory topics.
The company plans to initiate the Phase 3 study in the second half of 2026, following the completion of four engineering runs of AP-SA02 at its cGMP facility in Los Angeles. The total funding from the U.S.
Department of Defense for this project has reached $28.7 million. Additionally, Armata has received Fast Track Designation and an Initial Pediatric Study Plan from the FDA for AP-SA02, supporting its evaluation in pediatric patients. These developments may enhance Armata's market position and investor confidence as it advances its clinical programs.
Comments